Every material Form 8-K Sabra Health Care REIT filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sabra Health Care REIT reported third quarter 2026 total revenues of $249.6 million, up from $190.0 million a year earlier, and net income of $0.11 per diluted share, compared with $0.09. Normalized FFO was $0.39 per diluted share, up from $0.36, and the company updated 2026 normalized FFO guidance to $1.540 to $1.550 per share, which its CEO said was increased at the midpoint.
Total revenues were $249.6 million for the quarter, versus $190.0 million in the third quarter of 2025.
Normalized FFO was $0.39 per diluted share, versus $0.36; normalized AFFO was $0.41, versus $0.38.
Full-year 2026 guidance: net income $0.265 to $0.275 per share and normalized FFO $1.540 to $1.550 per share.
Sabra was awarded an additional $425 million of investments and declared a quarterly dividend of $0.30 per share, payable November 30, 2026.
Sabra Health Care REIT reported a second-quarter 2026 net loss of $0.10 per diluted share, compared with net income of $0.27 per diluted share a year earlier, after a $102.4 million provision for loan losses and other reserves. Total revenues rose to $235.9 million from $189.2 million, and normalized FFO per diluted share was $0.38 versus $0.37, while the company reiterated its full-year 2026 guidance.
Q2 2026 net loss of $0.10 per diluted share vs. net income of $0.27 in Q2 2025
Total revenues of $235.9 million vs. $189.2 million in Q2 2025; provision for loan losses and other reserves of $102.4 million
Normalized FFO of $0.38 per diluted share vs. $0.37; normalized AFFO of $0.40 vs. $0.38
Full-year 2026 guidance reiterated; quarterly dividend of $0.30 per share payable August 31, 2026
Sabra reported first quarter 2026 results, with total revenues of $221.8 million, up from $183.5 million a year earlier, and normalized FFO of $0.38 per diluted share, up from $0.35. Net income attributable to Sabra fell to $0.16 per diluted share from $0.17, and the company reiterated its full-year 2026 guidance and declared a $0.30 quarterly dividend.
Total revenues were $221.8 million for Q1 2026, compared with $183.5 million in Q1 2025.
Normalized FFO was $0.38 per diluted share, compared with $0.35; normalized AFFO was $0.39, compared with $0.37.
Net income attributable to Sabra was $40.9 million, or $0.16 per diluted share, compared with $40.3 million, or $0.17, a year earlier.
The board declared a $0.30 quarterly dividend payable May 29, 2026, to holders of record on May 15, 2026; full-year 2026 guidance was reiterated.
Sabra Health Care REIT reported fourth quarter 2025 total revenues of $211.9 million, up from $182.3 million a year earlier, but diluted net income fell to $0.11 per share from $0.19. Normalized FFO rose to $0.36 per share from $0.35 and normalized AFFO rose to $0.38 from $0.36. The company also initiated 2026 guidance for normalized FFO of $1.49 to $1.53 per share and normalized AFFO of $1.55 to $1.59 per share.
Q4 2025 diluted net income $0.11 per share vs $0.19 in Q4 2024; net loss on sales of real estate was $9.1 million in the quarter
Q4 2025 normalized FFO $0.36 per share vs $0.35; normalized AFFO $0.38 vs $0.36
2026 guidance: net income $0.60 to $0.64 per share; normalized FFO $1.49 to $1.53; normalized AFFO $1.55 to $1.59
Board declared a quarterly dividend of $0.30 per share, payable February 27, 2026 to holders of record on February 13, 2026
Sabra Health Care REIT appointed Darrin Smith, previously its Executive Vice President, Investments, as Chief Investment Officer, Secretary and Executive Vice President, succeeding Talya Nevo-Hacohen, who retired December 31, 2025. Michael Costa was also named Treasurer in addition to his role as Chief Financial Officer. The filing describes a routine executive transition with no financial results reported.
Darrin Smith appointed Chief Investment Officer, Secretary and Executive Vice President, effective January 1, 2026
Smith's employment agreement sets an initial annual base salary of $470,000 with a three-year initial term
Severance equals 1.5 times base salary plus average three-year bonus, rising to 2 times if termination occurs within two years of a change in control
Talya Nevo-Hacohen retired December 31, 2025 and will remain in a consulting role
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sabra Health Care REIT filing is on SEC EDGAR ↗. 8-K briefs of other companies →